Bli medlem
Bli medlem

Du är här

2014-06-12

AstraZeneca: AstraZeneca in-licenses Synairgen's SNG001 as a novel immuno-modulatory therapy for viral-induced exacerbation in asthma

Phase IIa clinical study to commence in patients with severe asthma

AstraZeneca today announced a global licence agreement with Synairgen
Plc, an AIM-listed UK company specialising in respiratory diseases,
for SNG001, a novel, inhaled interferon beta (IFN-beta) in clinical
development for treating respiratory tract viral infections in
patients with severe asthma. SNG001 supports the immune system by
correcting a deficiency which makes patients vulnerable to
respiratory tract viral infections.

Under the terms of the exclusive licence agreement, AstraZeneca will
pay Synairgen a $7.25 million up-front fee and potential development,
regulatory and commercial milestones of up to $225 million. In
addition, AstraZeneca will pay tiered royalties ranging from
single-digit up to mid-teens on commercial sales. AstraZeneca will be
responsible for future development costs.

In early 2015, AstraZeneca will commence a Phase IIa study in patients
with severe asthma, building on available clinical data from an
initial Phase lla trial in a broad asthma population. SNG001 also
provides the opportunity to expand the clinical programme in other
pulmonary diseases including chronic obstructive pulmonary disease
(COPD).

Maarten Kraan, Head of Respiratory, Inflammation & Autoimmune
Innovative Medicines, AstraZeneca, said: "Respiratory disease is a
core therapeutic area for AstraZeneca, and a key growth platform for
the company. Our approach includes addressing associated
complications that patients experience, as well as developing
treatments for the underlying disease. SNG001 is an innovative and
targeted therapy that has, if successful, the potential to offer a
step-change in the treatment of severe asthma, and possibly COPD."

Richard Marsden, Synairgen CEO, commented: "We're delighted that this
truly innovative programme, discovered at the University of
Southampton and developed by Synairgen, will be taken forward by
AstraZeneca. With its strong research focus and extensive experience
in respiratory disease, AstraZeneca's commitment to developing novel
medicines for patients with asthma and COPD makes them the ideal
partner for SNG001."

-ENDS-

NOTES TO EDITORS

About SNG001

SNG001 has a broad spectrum anti-viral effect and acts by delivering
IFN-beta to the lungs when an infection, such as a common cold,
begins to develop in the upper airways. Inhaled IFN-beta boosts the
anti-viral defence and combats the spread of the virus, preventing or
reducing the severity of exacerbations.

About respiratory viral infections

Respiratory viruses worsen symptoms in patients with asthma and COPD
leading to an inflammatory response and exacerbations. The reason for
the increased vulnerability of patients with pulmonary disease to
viral infections is thought to be a deficiency in their ability to
produce IFN-beta in the lungs. There is currently no effective
treatment option available, placing a burden on the health care
system due to the costs of hospital care.

About Synairgen Plc

Synairgen is a respiratory drug development company founded by
Professors Stephen Holgate, Donna Davies and Ratko Djukanovic at the
University of Southampton. Synairgen is quoted on AIM (LSE: SNG). For
more information about Synairgen, please see www.synairgen.com

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business
that focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of
cardiovascular, metabolic, respiratory, inflammation, autoimmune,
oncology, infection and neuroscience diseases. AstraZeneca operates
in over 100 countries and its innovative medicines are used by
millions of patients worldwide. For more information please visit:
www.astrazeneca.com.

CONTACTS

Media Enquiries

Esra Erkal-Paler +44 20 7604 8030 (UK/Global)

Vanessa Rhodes +44 20 7604 8037 (UK/Global)

Jacob Lund +46 8 553 260 20 (Sweden)

Michele Meixell + 1 302 885 6351 (US)

Investor Enquiries

Karl Hård +44 20 7604 8123  mob: +44 7789 654364

Colleen Proctor + 1 302 886 1842 mob: +1 302 357 4882

Anthony Brown +44 20 7604 8067 mob: +44 7585 404943

Jens Lindberg +44 20 7604 8414 mob: +44 7557 319729

-----------------------------------------------------------
http://news.cision.com/se/astrazeneca/r/astrazeneca-in-licenses-synairge...

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.